Update shared on 08 Nov 2025
Fair value Increased 16%OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.
Analyst Commentary
Bullish Takeaways- Several bullish analysts have raised their price targets for OptimizeRx, reflecting increased confidence in the company's future performance.
- Recent quarterly revenue significantly outperformed expectations, driving notable earnings outperformance and leading to upward adjustments in valuation targets.
- Analysts highlight ongoing momentum and improved operational visibility, especially following the company’s consistent beat of guidance and new forward-looking statements for 2026.
- There is a consensus that OptimizeRx is establishing a strong foundation for double-digit growth and expanding profit margins. Analysts point to effective execution and strategy evolution, such as the emphasis on subscription-based models.
- Despite positive outlooks, analysts caution about potential macroeconomic and policy-related risks that could impact demand for OptimizeRx's offerings.
- There is ongoing attention to possible regulatory changes in the pharmaceutical advertising landscape. These changes could affect traditional D2C channels and, in turn, influence OptimizeRx's growth trajectory.
- Some skepticism remains regarding the full impact and timing of the company’s transition to recurring subscription revenues, with execution risk noted.
What's in the News
- OptimizeRx provided new earnings guidance for the fiscal year 2026, projecting revenue between $118 million and $124 million. (Key Developments)
- The company raised its revenue guidance for fiscal year 2025 and now expects between $105 million and $109 million. (Key Developments)
- OptimizeRx announced a strategic partnership with Lamar Advertising Company to enhance out-of-home (OOH) advertising capabilities for pharmaceutical and healthcare brands using data-driven targeting. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target: Increased from $19 to $22.00 per share. This reflects a notable upward revision.
- Discount Rate: Increased slightly from 8.04% to 8.39%.
- Revenue Growth: The projected annual growth rate has increased from 8.02% to 9.14%.
- Net Profit Margin: Expanded from 4.20% to 7.64%, indicating greater profitability expectations.
- Future P/E Ratio: Decreased significantly from 82.12x to 48.97x, suggesting improved expected earnings and greater valuation efficiency.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.